UBS Maintains Buy on Veracyte, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 87.1%

Neg 0% Neu 0% Pos 87.1%

UBS analyst Lu Li maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $48 to $52.

Comments

No comments yet. Be the first!